Simon Weidlich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simon Weidlich has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Badertscher
Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland
3 shared publications - Sven Knecht
Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland
3 shared publications - Christian Sticherling
Department of Cardiology, University Hospital Basel, University Basel , Basel
2 shared publications Michael Kühne
Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland
2 shared publicationsAlan Kennedy
PulseAI, Belfast, United Kingdom
1 shared publicationBeat Schaer
Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 18 June 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (9) , 2003-2011
Inconclusive Single-Lead ECGs From Smart-Devices
- 18 June 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (9) , 2003-2011
Open AccessInconclusive Single-Lead ECGs From Smart-Devices
- Open Access
- 26 December 2023
- Published by Elsevier in Cardiovascular Digital Health Journal
- Vol. 5 (1) , 29-35
Reducing the burden of inconclusive smart device single-lead ECG tracings via a novel artificial intelligence algorithm
- 26 December 2023
- Published by Elsevier in Cardiovascular Digital Health Journal
- Vol. 5 (1) , 29-35
Open AccessReducing the burden of inconclusive smart device single-lead ECG tracings via a novel artificial intelligence algorithm
- Open Access
- 30 November 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (12)
Efficacy and safety of pulmonary vein isolation with pulsed field ablation vs. novel cryoballoon ablation system for atrial fibrillation
Pulsed-field ablation (PFA) has emerged as a novel treatment technology for patients with atrial fibrillation (AF). Cryoballoon (CB) is the most frequently used single shot technology. A direct comparison to a novel CB system is lacking. We aimed to compare pulmonary vein isolation (PVI) using PFA vs. a novel CB system regarding efficiency, safety, myocardial injury, and outcomes. One hundred and eighty-one consecutive patients underwent PVI and were included (age 64 ± 9.7 years, ejection fraction 0.58 ± 0.09, left atrial size 40 ± 6.4 mm, paroxysmal AF 64%). 106 patients (59%) underwent PFA (FARAPULSE, Boston Scientific) and 75 patients (41%) underwent CB ablation (PolarX, Boston Scientific). The median procedure time, left atrial dwell time and fluoroscopic time were similar between the PFA and the CB group with 55 [interquartile range (IQR) 43–64] min vs. 58 (IQR 48–69) min (P < 0.087), 38 (30–49) min vs. 37 (31–48) min, (P = 0.871), and 11 (IQR 9.3–14) min vs. 11 (IQR 8.7–16) min, (P < 0.81), respectively. Three procedural complications were observed in the PFA group (two tamponades, one temporary ST elevation) and three complications in the CB group (3× reversible phrenic nerve palsies). During the median follow-up of 404 days (IQR 208–560), AF recurrence was similar in the PFA group and the CB group with 24 vs. 30%, P = 0.406. Procedural characteristics were very similar between PFA and CB in regard to procedure duration fluoroscopy time and complications. Atrial fibrillation free survival did not differ between the PFA and CB groups. Comparison between pulsed field ablation and cryoballoon PolarX. AF, atrial fibrillation.
- 30 November 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (12)
Open AccessEfficacy and safety of pulmonary vein isolation with pulsed field ablation vs. novel cryoballoon ablation system for atrial fibrillation
Pulsed-field ablation (PFA) has emerged as a novel treatment technology for patients with atrial fibrillation (AF). Cryoballoon (CB) is the most frequently used single shot technology. A direct comparison to a novel CB system is lacking. We aimed to compare pulmonary vein isolation (PVI) using PFA vs. a novel CB system regarding efficiency, safety, myocardial injury, and outcomes. One hundred and eighty-one consecutive patients underwent PVI and were included (age 64 ± 9.7 years, ejection fraction 0.58 ± 0.09, left atrial size 40 ± 6.4 mm, paroxysmal AF 64%). 106 patients (59%) underwent PFA (FARAPULSE, Boston Scientific) and 75 patients (41%) underwent CB ablation (PolarX, Boston Scientific). The median procedure time, left atrial dwell time and fluoroscopic time were similar between the PFA and the CB group with 55 [interquartile range (IQR) 43–64] min vs. 58 (IQR 48–69) min (P < 0.087), 38 (30–49) min vs. 37 (31–48) min, (P = 0.871), and 11 (IQR 9.3–14) min vs. 11 (IQR 8.7–16) min, (P < 0.81), respectively. Three procedural complications were observed in the PFA group (two tamponades, one temporary ST elevation) and three complications in the CB group (3× reversible phrenic nerve palsies). During the median follow-up of 404 days (IQR 208–560), AF recurrence was similar in the PFA group and the CB group with 24 vs. 30%, P = 0.406. Procedural characteristics were very similar between PFA and CB in regard to procedure duration fluoroscopy time and complications. Atrial fibrillation free survival did not differ between the PFA and CB groups. Comparison between pulsed field ablation and cryoballoon PolarX. AF, atrial fibrillation.